Bank of Montreal’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-10,000
Closed -$7K 4575
2022
Q1
$7K Buy
+10,000
New +$8.49K ﹤0.01% 4036
2021
Q4
Sell
-438,907
Closed -$935K 3989
2021
Q3
$935K Buy
+438,907
New +$954K ﹤0.01% 2541
2020
Q1
Sell
-1,366
Closed -$7K 4901
2019
Q4
$7K Buy
1,366
+500
+58% +$2.77K ﹤0.01% 4646
2019
Q3
$5K Buy
866
+250
+41% +$1.72K ﹤0.01% 4566
2019
Q2
$4K Sell
616
-125
-17% -$952 ﹤0.01% 4707
2019
Q1
$8K Sell
741
-50
-6% -$498 ﹤0.01% 3947
2018
Q4
$6K Buy
791
+125
+19% +$1.8K ﹤0.01% 4061
2018
Q3
$13K Buy
666
+250
+60% +$4.55K ﹤0.01% 3856
2018
Q2
$8K Buy
416
+50
+14% +$737 ﹤0.01% 4027
2018
Q1
$4K Hold
366
﹤0.01% 3966
2017
Q4
$15K Hold
366
﹤0.01% 3678
2017
Q3
$20K Hold
366
﹤0.01% 3522
2017
Q2
$68K Hold
366
﹤0.01% 3119
2017
Q1
$44K Buy
+366
New +$38.4K ﹤0.01% 3132
2016
Q2
Sell
-125
Closed -$11K 4386
2016
Q1
$11K Buy
+125
New +$13.3K ﹤0.01% 3602

Other funds holding SIOX

Bank of Montreal's SIOX Position: Q2 2022 in Review

Bank of Montreal sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2022, closing a stake of 10,000 shares — an estimated $7K sold.

Bank of Montreal first reported a position in SIOX in Q1 2016 and held it in 15 quarters. The position peaked at $935K in Q3 2021. 41 funds tracked by Wall St. Rank hold SIOX as of Q2 2022.

  • Bank of Montreal reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bank of Montreal sold 10,000 Sio Gene Therapies Inc. Common Stock shares in Q2 2022, an estimated $7K.
  • Bank of Montreal first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2016 and held it in 15 quarters.
  • Bank of Montreal's Sio Gene Therapies Inc. Common Stock position peaked at $935K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2022.

Based on Bank of Montreal's 13F filing for Q2 2022, filed 11 Aug 2022.